SCHEMBL16077822

SCHEMBL16077822

CCc1c(Cc2cccnc2)[nH]c2c(C#N)cnn2c1=O

nearest known ligand 0.42

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
▸ KDM5A P29375 5/20 0.42
▸ CSNK2A1 P68400 1/20 0.38
▸ PDE4A P27815 1/20 0.36
▸ PDE4B Q07343 1/20 0.36
▸ PDE4C Q08493 1/20 0.36
▸ PDE4D Q08499 1/20 0.36
▸ HPGD P15428 3/20 0.36
▸ ALDH1A1 P00352 2/20 0.36
▸ MAPT P10636 1/20 0.36
▸ HIF1A Q16665 1/20 0.36
▸ KDM4D Q6B0I6 1/20 0.36
▸ PLAT P00750 1/20 0.35
▸ PLA2G7 Q13093 1/20 0.35
▸ CASP1 P29466 3/20 0.35
▸ HSD17B10 Q99714 3/20 0.35
▸ CASP7 P55210 2/20 0.35
▸ KDM4E B2RXH2 2/20 0.35
▸ GLA P06280 1/20 0.35
▸ GAA P10253 1/20 0.35
▸ GFER P55789 1/20 0.35

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL16046157 0.89 KDM5A (0.46) KDM5ACSNK2A1HPGDALDH1A1MAPT
SCHEMBL16077832 0.87 KDM5A (0.46) KDM5AALDH1A1KDM4DPLATHSD17B10
SCHEMBL18159119 0.82 KDM5A (0.53) KDM5AHPGDALDH1A1KDM4DPLAT
SCHEMBL16077831 0.81 KDM4E (0.40) KDM5APLATKDM4EMEN1KMT2A
SCHEMBL16077839 0.80 KDM5A (0.42) KDM5AALDH1A1KDM4DPLATPLA2G7
SCHEMBL16047075 0.80 KDM5A (0.49) KDM5AHPGDALDH1A1KDM4DPLAT
SCHEMBL16077833 0.79 KDM5A (0.42) KDM5AALDH1A1KDM4DHSD17B10KDM4E
SCHEMBL16048043 0.79 KDM5A (0.50) KDM5AHPGDALDH1A1KDM4DPLAT
SCHEMBL16047129 0.79 KDM5A (0.50) KDM5AHPGDALDH1A1KDM4DPLAT
SCHEMBL16046459 0.77 KDM5A (0.48) KDM5AHPGDALDH1A1MAPTKDM4D

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 7 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-20220202792-A1 METHODS AND COMPOSITIONS FOR TREATING CHRONIC INFLAMMATORY INJURY, METAPLASIA, DYSPLASIA AND CANCERS OF EPITHELIAL TISSUES UNIVERSITY OF HOUSTON SYSTEM (US) 2022-06-30 — — US disclosed
WO-2020219963-A1 METHODS AND COMPOSITIONS FOR TREATING CHRONIC INFLAMMATORY INJURY, METAPLASIA, DYSPLASIA AND CANCERS OF EPITHELIAL TISSUES UNIVERSITY OF HOUSTON SYSTEM (US) 2020-10-29 — — WO disclosed
US-10035801-B2 Pyrazolo compounds and uses thereof GENENTECH, INC. (US) 2018-07-31 — — US disclosed
US-20160060267-A1 PYRAZOLO COMPOUNDS AND USES THEREOF GENENTECH, INC. (US) 2016-03-03 — — US disclosed
US-20140275092-A1 PYRAZOLO COMPOUNDS AND USES THEREOF CONSTELLATION PHARMACEUTICALS, INC. (US) 2014-09-18 — — US disclosed
US-20140275092-A1 PYRAZOLO COMPOUNDS AND USES THEREOF CONSTELLATION PHARMACEUTICALS, INC. (US) 2014-09-18 — — US disclosed
WO-2014139326-A1 PYRAZOLO COMPOUNDS AND USES THEREOF GENENTECH, INC. (US) 2014-09-18 — — WO disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (4 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-10035801-B2 Pyrazolo compounds and uses thereof KDM5A, KDM5C, KDM5B KDM5A 1/4885CSNK2A1 921/4885PDE4A 520/4885
US-20140275092-A1 PYRAZOLO COMPOUNDS AND USES THEREOF KDM1B, DOT1L, EHMT1 KDM5A 4/4885CSNK2A1 1315/4885PDE4A 224/4885
US-20160060267-A1 PYRAZOLO COMPOUNDS AND USES THEREOF KDM5A, KDM5C, KDM5B KDM5A 1/4885CSNK2A1 921/4885PDE4A 520/4885
US-20220202792-A1 METHODS AND COMPOSITIONS FOR TREATING CHRONIC INFLAMMATORY INJURY, METAPLASIA, DYSPLASIA AND CANCERS OF EPITHELIAL TISSUES FABP2, MUC1, FABP6 KDM5A 4362/4885CSNK2A1 2357/4885PDE4A 1309/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.

Send feedback